Canurta Journal

In 2023, the U.S. Food and Drug Administration (FDA) approved 55 new drugs, marking a significant year in pharmaceutical advancements....

July 31, 2024 – Toronto, Canada: Canurta Therapeutics is pleased to announce the granting of its first US patent for the company’s...

The advent of Artificial Intelligence (AI) is revolutionizing the nutraceutical industry, transitioning from traditional development...

This week, I had the opportunity to attend the ALS Drug Development Summit in Boston, an event that brought together the brightest minds...

We are pleased to announce a significant transformation in our corporate structure and brand architecture. The organization will now have...

The Company has received $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC...

We're excited to announce that our CEO, Akeem Gardner, was recently interviewed by the Ontario Centre of Innovation (OCI) about the...

Letter from our CEO I am writing to you today as the CEO of our company in the biotech and agricultural industries. I understand that...

Given the scarcity of Canurta’s novel molecules, they have never been formally assayed in animal or human models. Canurta has committed...